Epigral Ltd

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid sector-wide valuation disparities and company-specific performance metrics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has reported a stabilisation in its financial trend for the quarter ended June 2026, shifting from a negative trajectory to a flat performance. Despite some encouraging signs in operating profit and quarterly earnings growth, the company continues to face challenges in return on capital and cash reserves, reflecting a mixed outlook for investors.

Epigral Ltd., a specialty chemicals manufacturer with a market capitalisation of ₹5,088 crores, reported a mixed performance in Q1 FY27, with consolidated net profit rising 23.21% quarter-on-quarter to ₹99.74 crores despite a 4.18% decline in net sales. The company's shares traded at ₹1,159.75 on July 27, down 37.28% over the past year, significantly underperforming the broader Sensex and the specialty chemicals sector.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, reflected in a 7.49% surge in its share price to ₹1,164.45 on 22 Jul 2026. This movement comes amid a complex backdrop of mixed technical indicators, signalling a transition from a bearish to a mildly bearish trend, with implications for investors assessing the stock’s near-term prospects.

The Sensex edged down 0.11% on 21 Jul 2026, while Epigral Ltd surged 7.08%, outpacing its Specialty Chemicals sector by 7 percentage points. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which has been on a two-day winning streak, accumulating a 10.56% return in that period.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

The Sensex declined by 0.38% on 13 Jul 2026, while Epigral Ltd surged 10.82% to an intraday high of Rs 1082. This 10.83-percentage-point outperformance over its Specialty Chemicals sector peers highlights a distinctly stock-specific rally rather than a market-wide uplift.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, reflecting a deteriorating market sentiment. Recent technical indicators reveal a transition from mildly bearish to outright bearish trends, with key momentum oscillators and moving averages signalling caution for investors amid a sustained price decline.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 May 2026, providing investors with an up-to-date view of its performance and outlook.